BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)
February 24, 2025 1:18 PM ESTPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $23.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "Remain OW rated on BCRX shares after a solid Q424 Orladeyo print, reporting $124.2M versus the $123.5M preliminary revenue pre-released last month.... More
JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)
February 24, 2025 8:58 AM ESTJPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "We think the ~3% upward guidance revision to FY25 Orladeyo revs by ~$18mm at the midpoint to $535-$550mm (vs prior guidance of $515-$535mm established earlier this year at our healthcare conference) will be well received as it supports 24% growth YoY for Orladeyo at the midpoint after 34% Orladeyo growth in 24. Well listen... More
